Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.23
+0.56500.87%
Pre-market: 65.650.4240+0.65%08:57 EDT
Volume:2.30M
Turnover:150.51M
Market Cap:12.61B
PE:172.12
High:66.30
Open:65.95
Low:64.33
Close:64.67
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.46
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.99
PE(LYR):36.24

Loading ...

BioMarin says VOXZOGO long-term trials improve arm span, maintain bone density in achondroplasia

Reuters
·
May 03

Biomarin Presents New Data on the Effect of Long-Term Treatment With Voxzogo® (Vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

THOMSON REUTERS
·
May 03

BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a share - Earnings Preview

Reuters
·
May 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

MT Newswires Live
·
Apr 27

BioMarin completes acquisition of Amicus Therapeutics

TIPRANKS
·
Apr 27

BioMarin completes Amicus acquisition for USD 14.5 per share, valuing deal at USD 4.8 billion

Reuters
·
Apr 27

Biomarin Completes Acquisition of Amicus Therapeutics

THOMSON REUTERS
·
Apr 27

BioMarin to host first-quarter results conference call and webcast

Reuters
·
Apr 27

Morgan Stanley Resumes BioMarin Pharmaceutical at Overweight With $120 Price Target

MT Newswires Live
·
Apr 27

BioMarin resumed with an Overweight at Morgan Stanley

TIPRANKS
·
Apr 27

Piper Sandler Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 24

BioMarin wins French FDI clearance for Amicus merger, closing expected April 27

Reuters
·
Apr 24

Biomarin Pharmaceutical Inc - France Grants Fdi Clearance for Biomarin-Amicus Merger on April 23, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 24

BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial

TIPRANKS
·
Apr 24

BRIEF-Biomarin Announces Board Leadership Transition

Reuters
·
Apr 22

Biomarin Pharmaceutical Inc - Richard a. Meier to Retire From Board After Annual Meeting

THOMSON REUTERS
·
Apr 22

Press Release: BioMarin Announces Board Leadership Transition

Dow Jones
·
Apr 22

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall

Simply Wall St.
·
Apr 10

RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 09